Kazuya Tsuboi

Nagoya, 4530801, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 14 publications

Detection of mulberry bodies using molecular imaging flow cytometry.

Detection of mulberry bodies using molecular imaging flow cytometry.

Journal: Clinical and experimental nephrology

Published: April 21, 2025

Prevalence of patients with lysosomal storage disorders and peroxisomal disorders: A nationwide survey in Japan.

Prevalence of patients with lysosomal storage disorders and peroxisomal disorders: A nationwide survey in Japan.

Journal: Molecular genetics and metabolism

Published: February 24, 2021

Detection of novel Fabry disease-associated pathogenic variants in Japanese patients by newborn and high-risk screening.

Detection of novel Fabry disease-associated pathogenic variants in Japanese patients by newborn and high-risk screening.

Journal: Molecular genetics & genomic medicine

Published: April 29, 2020

Otological aspects of Fabry disease in patients with normal hearing.

Otological aspects of Fabry disease in patients with normal hearing.

Journal: Nagoya journal of medical science

Published: October 04, 2019

Potential prognostic implications of myocardial thallium-201 and iodine-123-beta-methylpentadecanoic acid dual scintigraphy in patients with Anderson-Fabry disease.

Potential prognostic implications of myocardial thallium-201 and iodine-123-beta-methylpentadecanoic acid dual scintigraphy in patients with Anderson-Fabry disease.

Journal: Annals of nuclear medicine

Published: August 16, 2019

Skin Lesion in Fabry Disease

Skin Lesion in Fabry Disease

Journal: Brain and nerve = Shinkei kenkyu no shinpo

Published: April 17, 2019

Correlations Between Serum Cholesterol and Vascular Lesions in Fabry Disease Patients.

Correlations Between Serum Cholesterol and Vascular Lesions in Fabry Disease Patients.

Journal: Circulation journal : official journal of the Japanese Circulation Society

Published: October 05, 2018

Efficacy and safety of enzyme-replacement-therapy with agalsidase alfa in 36 treatment-naïve Fabry disease patients.

Efficacy and safety of enzyme-replacement-therapy with agalsidase alfa in 36 treatment-naïve Fabry disease patients.

Journal: BMC pharmacology & toxicology

Published: February 24, 2017

Successful management of enzyme replacement therapy in related fabry disease patients with severe adverse events by switching from agalsidase Beta (fabrazyme(®)) to agalsidase alfa (replagal (®)).

Successful management of enzyme replacement therapy in related fabry disease patients with severe adverse events by switching from agalsidase Beta (fabrazyme(®)) to agalsidase alfa (replagal (®)).

Journal: JIMD reports

Published: October 02, 2013

Clinical course of patients with Fabry disease who were switched from agalsidase-β to agalsidase-α.

Clinical course of patients with Fabry disease who were switched from agalsidase-β to agalsidase-α.

Journal: Genetics in medicine : official journal of the American College of Medical Genetics

Published: September 30, 2013

Clinical observation of patients with Fabry disease after switching from agalsidase beta (Fabrazyme) to agalsidase alfa (Replagal).

Clinical observation of patients with Fabry disease after switching from agalsidase beta (Fabrazyme) to agalsidase alfa (Replagal).

Journal: Genetics in medicine : official journal of the American College of Medical Genetics

Published: August 11, 2012

Descriptive epidemiology of Fabry disease among beneficiaries of the Specified Disease Treatment Research Program in Japan.

Descriptive epidemiology of Fabry disease among beneficiaries of the Specified Disease Treatment Research Program in Japan.

Journal: Journal of epidemiology

Published: July 14, 2012

Showing 1-12 of 14

Last Updated: 09/26/2026